Acromegaly Update

A thin top-tier week for acromegaly (one Pituitary paper plus a handful of solid next-tier studies, including a 2026 pipeline review), while rare disease news was dominated by positive Phase 3 readouts from Disc Medicine and Roivant, a second FDA look at Biohaven's ataxia drug, and early Huntington's data from Alnylam.

A thin week: no top-tier-journal acromegaly papers appeared, so Part A draws on the next tier (a radiomics model to predict somatostatin-analog response, a familial Carney-complex case, and bone proteomics), while the rare disease industry's big story is uniQure's four-year Huntington's gene therapy data, which showed a smaller, non-significant benefit and sent the stock down about 40%.

A quiet week for top-tier acromegaly literature (four papers, mostly real-world/consensus rather than trial data) paired with a livelier rare disease industry week — a first-ever positive pivotal trial in X-linked retinitis pigmentosa and a new FOP approval that goes head-to-head with Regeneron — while Marea's own MAR002 acromegaly program remains the clearest bridge between the two segments follo...

This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.

It's a quiet week for acromegaly-specific research — just one review paper worth flagging — but rare disease industry news was busy, headlined by Scholar Rock's first-ever muscle-targeted SMA approval and a rough week for two RNA-based rare disease programs at Novartis.

It's a thin week for acromegaly-specific research — no top-tier-journal hits, so we're covering the best next-tier evidence on GH-axis physiology, octreotide drug delivery, and pituitary imaging AI — while rare disease industry news delivers a sharp one-two: Ionis just won the first-ever approval for Alexander disease, days after Ultragenyx's marquee Angelman syndrome drug flopped in Phase 3.

It's a quiet week for dedicated acromegaly research — no top-tier-journal hits, just a pasireotide cost-effectiveness review and a giant-adenoma case report — while the wider rare disease industry absorbed a surprise Phase 3 failure in the ATTR-CM heart drug market and a fresh round of White House drug-pricing deals touching major rare-disease manufacturers.

It's a quiet week for acromegaly-specific research — no top-tier trials, just a handful of diagnostic and mechanistic papers — while rare disease industry news brought two new FDA approvals (Priovant's Lisraya for dermatomyositis and Takeda/Protagonist's Mimrylo for polycythemia vera) that show regulators keep clearing novel mechanisms for small patient populations.

It was a quiet week for acromegaly-specific research — three observational studies refined how we monitor and support patients rather than changing treatment — while the wider rare disease industry saw two major FDA approvals and two sizable M&A deals land within days of each other.

It's an unusually rich week for acromegaly research — five new papers spanning a first-in-human antagonist trial and two large Swedish outcomes studies — while the rare disease industry saw a $1.3B rare-epilepsy buyout, a bankruptcy-auction gene therapy pickup, and a safety scare over a newly approved Prader-Willi drug.

It's a quiet week for acromegaly-specific trial data — the research side leans mechanistic and clinical-management, headlined by a novel long-acting GH receptor antagonist — while rare disease industry news brought a fresh Phase 2 win for Silence Therapeutics, an $800M Stargardt disease acquisition, a CRISPR safety insight from Intellia, and a Washington fight over whether orphan drugs get carved...

It's a quiet week for acromegaly-specific research — no trials, just incremental papers on AI-assisted detection, surgical outcomes, and pediatric gigantism — while the broader rare disease industry saw a gene-editing "gold rush" for a liver/lung disorder, a financing bet against two bigger rivals in Angelman syndrome, and a pulmonary hypertension partnership fall apart after a near-miss trial.

A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing startup inked a licensing deal and orphan drugmakers pushed back on Medicare price-pilot exposure.

A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.

It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecas...

New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

New proteomic biomarkers could sharpen acromegaly diagnosis beyond GH/IGF-1, while the rare disease industry sees a wave of FDA decisions and high-stakes M&A activity.

Acromegaly research this week centered on the long-term pharmacology of established therapies and clinical management updates, while the rare disease industry absorbed significant regulatory and pipeline news.

This week's literature brings a long-term safety confirmation for pegvisomant monotherapy, a head-to-head comparison of first-generation somatostatin analogs using a validated composite score, and new evidence linking acromegaly to hepatic steatosis — alongside cost-effectiveness data for pasireotide and updated pituitary tumor pathology tools.